Latest Content

DSM’s future adds biomarkers and context, yet validity remains unresolved—are diagnoses real? Critics urge an evidence-based overhaul.

Experts explain how careful pediatric psychopharmacology and early intervention protect development, curb relapse, and address substance-use risk.

Check out the pipeline updates from May!

Real-world claims show opioids remain common in fibromyalgia despite guidance, highlighting safety concerns and interest in FDA-approved non-opioid option Tonmya.

Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.

FDA clears Modius Spero headset, a noninvasive at-home neuromodulation therapy that eases PTSD symptoms, with veterans first to access via VA.

Explore psychopharmacologic options for personality disorders in this podcast.

Explore how integrated psychotherapy—CBTp, family support, and humane alliance—reduces relapse and restores meaning beyond medication in schizophrenia.

New Surgeon General advisory warns of youth screen and social media harms, urging families, schools, and clinicians to act with the 5 Ds.

In this CME article, explore a 4-stage framework that detects suicide risk without ideation disclosure, guiding clinicians to spot crisis signs and act fast.

Synendos launches a phase 2 trial of SYT-510, a first-in-class endocannabinoid modulator, aiming to ease generalized anxiety symptoms with improved safety and adherence.

Four fathers share real-time signs of suicide crisis syndrome—insomnia, agitation, withdrawal—showing why standard screening misses imminent danger.

Real-world registry data reveals young adults with mood disorders face high TD burden yet low diagnosis rates, spotlighting urgent screening gaps.